ReviewPerioperative medicine (London, England)2026
Perioperative neurocognitive disorders in older patients: a narrative review of current knowledge in 2026.
Review in Perioperative medicine (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Perioperative neurocognitive disorders (PNDs) are frequent and severe complications in older surgical patients, encompassing postoperative delirium, delayed neurocognitive recovery, postoperative neurocognitive disorder, and long-term cognitive impairment. These complications lead to prolonged hospital stay, elevated medical expenditure, and compromised long-term quality of life. In this 2026 narrative review, we systematically outline up-to-date evidence on the pathophysiology, risk factors, screening approaches, and evidence-based interventions for PNDs. The core mechanisms involve neuroinflammation, gut microbiota dysbiosis, blood-brain barrier disruption, cerebral hypoperfusion, oxidative stress, and tau hyperphosphorylation. Key risk factors include advanced age, preoperative cognitive impairment or frailty, intraoperative hypotension, deep anesthesia, hypothermia, cardiopulmonary bypass, and suboptimal postoperative pain and sleep control. Bedside tools (Mini-Cog, MoCA, MMSE, FRAIL scale) permit feasible risk stratification; tau-PT217, NfL, S100A12, and GFAP are emerging predictive biomarkers. Dexmedetomidine is a pharmacologic agent that has been extensively studied and has relatively strong supporting evidence. Non-pharmacological interventions and multidisciplinary care are recommended as first-line strategies. Outstanding issues include optimal intraoperative hemodynamic and anesthetic thresholds, causal links between delirium and long-term cognitive decline, and clinical validation of biomarkers. Future research demands large-scale multicenter randomized controlled trials and standardized workflows to strengthen personalized perioperative brain protection in elderly surgical patients.
Indexed as
Identifiers
42399998What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.